Mutant E1A Stabilization for Oncolytic Adenovirus Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic adenoviruses face limitations such as the need for improved lysogenic potency and rejection by tumor cells due to ubiquitination-mediated degradation of the E1A protein.
Innovation Solution
A mutant E1A is developed by mutating lysine residues at positions 253 and 285 to arginine, reducing ubiquitination-mediated degradation and maintaining high-level expression of the E1A protein, thereby enhancing the replication and tumor-killing effect of oncolytic adenoviruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type E1A is used in oncolytic adenoviruses, then the virus can replicate in tumor cells, but the E1A protein is degraded by ubiquitination-mediated degradation, reducing viral replication potency
Solution Approach 1:
The patent applies parameter changes by mutating specific amino acid residues (lysine to arginine) at positions 253 and 285 in the E1A protein sequence. This molecular parameter modification prevents ubiquitination-mediated degradation, thereby stabilizing the E1A protein and enhancing viral replication potency in tumor cells.
2Productivity
If oncolytic adenoviruses are used to treat tumors, then tumor cells are lysed and destroyed, but the virus is rejected by tumor cells due to E1A degradation
Solution Approach 1:
The patent modifies the E1A protein parameters through specific amino acid mutations (K253R and K285R) that prevent recognition by tumor cell ubiquitination machinery. This parameter change enables the virus to evade tumor cell rejection while maintaining its oncolytic activity and killing efficacy.
3Reliability
If lysine residues at positions 253 and 285 are mutated to arginine in E1A, then ubiquitination-mediated degradation is reduced and E1A expression is maintained at high levels, but the mutation process requires precise genetic engineering
Solution Approach 1:
The patent employs parameter changes through site-directed mutagenesis to introduce specific amino acid substitutions (lysine to arginine) at positions 253 and 285 in the E1A gene. This precise genetic modification stabilizes the E1A protein and can be achieved through standard molecular biology techniques, balancing manufacturing feasibility with protein stability enhancement.
Data Source
AI summary
A mutant E1A antagonizing ubiquitination-mediated degradation and its use in the preparation of potentiated oncolytic adenoviruses and immune potentiators are provided. The mutant E1A is obtained by mutating lysine residues at positions 253 and 285 of a wild-type E1A to any one of glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, aspartic acid, glutamic acid, arginine, or histidine. The mutation is capable of reducing the degradation of a key adenoviral replication protein E1A and maintaining its high level expression, thereby promoting replication of oncolytic adenovirus, improving tumor killing effect, and holding broad clinical application prospects.